All LLY Content

Eli Lilly and Company (LLY) Foundayo™ (orforglipron), Lilly’s new oral GLP-1 pill for weight loss, now available in the U.S.

Eli Lilly and Company (NYSE: LLY) FY 2026 Product Release

April 9, 20261 min read

Eli Lilly and Company (LLY) Lilly To Acquire Centessa Pharmaceuticals To Advance Treatments For Sleep-Wake Disorders

Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release

March 31, 20261 min read

Eli Lilly and Company (LLY) Phase 3b data presented at AAD Annual Meeting show Lilly’s Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity

Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release

March 29, 20261 min read

Eli Lilly and Company (LLY) Lilly’s EBGLYSS (Lebrikizumab-Lbkz) Delivered Up To Four Years Of Durable Disease Control For Patients With Moderate-To-Severe Atopic Dermatitis

Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release

March 27, 20261 min read

Eli Lilly and Company (LLY) Lilly’s triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes

Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release

March 19, 20261 min read

Eli Lilly and Company (LLY) Lilly’s EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitis

Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release

March 16, 20261 min read

Eli Lilly and Company (LLY) Q4 2025 Earnings Call Transcript

Eli Lilly and Company (NYSE: LLY) Q4 2025 Earnings Call dated Feb. 04, 2026 Corporate Participants: Mike Czapar — Director...

March 10, 202650 min read

Eli Lilly and Company (LLY) Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patients

Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release

March 5, 20261 min read

Eli Lilly and Company (LLY) Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion

Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release

March 3, 20261 min read

Eli Lilly and Company (LLY) Lilly’s Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata

Eli Lilly and Company (NYSE: LLY) FY 2026 Other Release

February 27, 20261 min read